Deciphera Pharmaceuticals Llc Stock Beneish M Score
| DCPH Stock | USD 25.48 0.01 0.04% |
Deciphera | Beneish M Score |
At this time, Deciphera Pharmaceuticals' M Score is unavailable. The earnings manipulation may begin if Deciphera Pharmaceuticals' top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by Deciphera Pharmaceuticals executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of Deciphera Pharmaceuticals' earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-3.35
Beneish M Score - Unavailable
Deciphera Pharmaceuticals Beneish M-Score Indicator Trends
The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if Deciphera Pharmaceuticals' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Net Receivables | 24.4 M | 32 M |
|
| |||||
| Total Assets | 393.8 M | 473.6 M |
|
| |||||
| Total Current Assets | 351.3 M | 381.1 M |
|
| |||||
| Non Current Assets Total | 97.1 M | 92.5 M |
|
| |||||
| Property Plant Equipment | 9.3 M | 7.7 M |
|
| |||||
| Depreciation And Amortization | 3 M | 2.1 M |
|
| |||||
| Selling General Administrative | 74.7 M | 129.5 M |
|
| |||||
| Total Current Liabilities | 56 M | 100.3 M |
|
| |||||
| Non Current Liabilities Total | 41.6 M | 22.4 M |
|
| |||||
| Short Term Debt | 1.8 M | 3.5 M |
|
| |||||
| Long Term Debt | 1.1 M | 996.3 K |
|
| |||||
| Long Term Investments | 49 M | 46.7 M |
|
| |||||
| Gross Profit Margin | 1.07 | 0.9772 |
|
|
Deciphera Pharmaceuticals Beneish M-Score Driver Matrix
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between Deciphera Pharmaceuticals' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Deciphera Pharmaceuticals in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find Deciphera Pharmaceuticals' degree of accounting gimmicks and manipulations.
Click cells to compare fundamentals
About Deciphera Pharmaceuticals Beneish M Score
M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.
Depreciation And Amortization |
|
Deciphera Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Deciphera Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Deciphera Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
About Deciphera Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Deciphera Pharmaceuticals LLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Deciphera Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Deciphera Pharmaceuticals LLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Deciphera Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Deciphera Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Deciphera Pharmaceuticals Llc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Deciphera Pharmaceuticals Llc Stock:Check out Deciphera Pharmaceuticals Piotroski F Score and Deciphera Pharmaceuticals Altman Z Score analysis. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for Deciphera Stock analysis
When running Deciphera Pharmaceuticals' price analysis, check to measure Deciphera Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Deciphera Pharmaceuticals is operating at the current time. Most of Deciphera Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Deciphera Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Deciphera Pharmaceuticals' price. Additionally, you may evaluate how the addition of Deciphera Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| CEOs Directory Screen CEOs from public companies around the world | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |
Is Deciphera Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Deciphera Pharmaceuticals. If investors know Deciphera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Deciphera Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.21) | Revenue Per Share 2.028 | Quarterly Revenue Growth 0.345 | Return On Assets (0.27) | Return On Equity (0.50) |
The market value of Deciphera Pharmaceuticals is measured differently than its book value, which is the value of Deciphera that is recorded on the company's balance sheet. Investors also form their own opinion of Deciphera Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Deciphera Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Deciphera Pharmaceuticals' market value can be influenced by many factors that don't directly affect Deciphera Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Deciphera Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Deciphera Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Deciphera Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.